NovImmune has currently seven promising monoclonal antibodies for the treatment of immune-related disorders in its pipeline with a balance of clinical and preclinical compounds. The most advanced is in clinical development phase II.
Each product, driven by its mechanism of action, has the potential to ultimately become a medicine for multiple diseases. 

Acronyms:
TBD: To Be Determined
PBC: Primary Biliary Cirrhosis
HLH: Hemophagocytic lymphohistiocytosis